New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 11, 2012
12:47 EDTSGYPSynergy Pharmaceuticals announces extension for Q3 10-Q filing due to hurricane
Synergy Pharmaceuticals announced that, in accordance with applicable rules issued by the United States Securities and Exchange Commission, it will delay, for a short period, the filing of its quarterly Report on Form 10-Q for the three and nine months ended September 30, 2012. The company's normal process for compilation and review of its financial statements was delayed due to the company's accounting personnel not being able to travel to the company's headquarters and not being able to access the company's accounting records due to the effects of Hurricane Sandy.
News For SGYP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 15, 2015
08:21 EDTSGYPSynergy upside largely dependent on buyout, says Citi
Citi doubled its price target for Synergy Pharmaceuticals (SGYP) to $12 from $6 but cautions that upside from current levels is likely dependent on a potential takeout. The firm sees raised expectations into the new the data readout for plecanatide. The drug's effectiveness in chronic idiopathic constipation looks fairly similar to Ironwood's (IRWD) Linzess, Citi tells investors in a research note. It keeps a Buy rating on Synergy.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use